Concomitant medication of psychoses in a lifetime perspective

Human Psychopharmacology

Volumn 26, Issue 4-5, 2011, Pages 322-331

  Vares, Maria ^a   Saetre, Peter ^a   Stralin, Pontus ^a   Levander, Sten ^b   Lindström, Eva ^c   Jönsson, Erik G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MALMÖ UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

antipsychotic drugs; concomitant medication; lifetime; poly pharmacy; retrospective; schizophrenia

Indexed keywords

ALPRAZOLAM; AMILORIDE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BENDROFLUMETHIAZIDE; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; BUSPIRONE; CARDIOVASCULAR AGENT; CITALOPRAM; CLOMIPRAMINE; DISULFIRAM; DRUGS USED IN THE TREATMENT OF ADDICTION; FLUOXETINE; HYDROCHLOROTHIAZIDE; HYPNOTIC AGENT; IMIPRAMINE; LITHIUM; MAPROTILINE; MIANSERIN; MOOD STABILIZER; NEFAZODONE; PHENOBARBITAL; PHENYTOIN; SEDATIVE AGENT; UNINDEXED DRUG;

ADULT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALS, URBAN; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SWEDEN; YOUNG ADULT;

EID: 79960847925     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1209     Document Type: Review

References (85)

1. Addington DD, Azorin JM, Falloon IR, Gerlach J, Hirsch SR, Siris SG,. 2002. Clinical issues related to depression in schizophrenia: an international survey of psychiatrists. Acta Psychiatr Scand 105: 189-195. (Pubitemid 34280691)
2. American Psychiatric Association. 1987. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn-Revised. American Psychiatric Association: Washington DC.
3. American Psychiatric Association. 1995. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, International Version. American Psychiatric Association: Washington DC.
4. Battaglia J,. 2005. Pharmacological management of acute agitation. Drugs 65: 1207-1222. (Pubitemid 41032047)
5. Borison RL,. 1983. Amantadine in the management of extrapyramidal side effects. Clin Neuropharmacol 6 (Suppl 1): S57-S63. (Pubitemid 14243361)
6. Breslau N, Davis GC,. 1993. Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults. J Psychiatr Res 27: 211-221. (Pubitemid 23234204)
7. Cantor-Graae E, Nordstrom LG, McNeil TF,. 2001. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 48: 69-82. (Pubitemid 32241184)
8. Caton CL, Shrout PE, Eagle PF, Opler LA, Felix A,. 1994. Correlates of codisorders in homeless and never homeless indigent schizophrenic men. Psychol Med 24: 681-688. (Pubitemid 24265751)
9. Citrome L,. 2009. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother 9: 55-71.
10. Citrome L, Goldberg JF, Stahl SM,. 2005. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry 13: 28-42. (Pubitemid 40446363)
11. Drake RE, Xie H, McHugo GJ, Green AI,. 2000. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26: 441-449. (Pubitemid 30423220)
12. Dusitanond P, Young WB,. 2009. Neuroleptics and migraine. Cent Nerv Syst Agents Med Chem 9: 63-70.
13. Edlinger M, Hausmann A, Kemmler G, et al,. 2005. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res 77: 25-34. (Pubitemid 40957058)
14. Ekholm B, Ekholm A, Adolfsson R, et al,. 2005. Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord J Psychiatry 59: 457-464. (Pubitemid 41801793)
15. Eriksson M, Holmgren L, Janlert U, et al,. 2011. Large improvements in major cardiovascular risk factors in the population of northern Sweden: the MONICA study 1986-2009. J Intern Med 269: 219-231.
16. Ettinger AB, Argoff CE,. 2007. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 4: 75-83. (Pubitemid 46110806)
17. Galletti F, Cupini LM, Corbelli I, Calabresi P, Sarchielli P,. 2009. Pathophysiological basis of migraine prophylaxis. Prog Neurobiol 89: 176-192.
18. Gerlach J,. 2002. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 14: 47-57. (Pubitemid 34538832)
19. Gillies D, Beck A, McCloud A, Rathbone J, Gilles D,. 2005. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev (4): CD003079.
20. Glick ID, Zaninelli R, Hsu C, et al,. 2004. Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. J Clin Psychiatry 65: 679-685.
21. Gray R, Gournay K,. 2000. What can we do about acute extrapyramidal symptoms? J Psychiatr Ment Health Nurs 7: 205-211.
22. Green AI, Noordsy DL, Brunette MF, O'Keefe C,. 2008. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 34: 61-71. (Pubitemid 350216350)
23. Hamel E,. 2007. Serotonin and migraine: biology and clinical implications. Cephalalgia 27: 1293-1300.
24. Haro JM, Salvador-Carulla L,. 2006. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 20: 293-301.
25. Haspel T,. 1995. Beta-blockers and the treatment of aggression. Harv Rev Psychiatry 2: 274-281.
26. Hayes PE, Schulz SC,. 1983. The use of beta-adrenergic blocking agents in anxiety disorders and schizophrenia. Pharmacotherapy 3: 101-117. (Pubitemid 13055673)
27. Hedlund PB,. 2009. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 206: 345-354.
28. Huf G, Alexander J, Allen MH,. 2005. Haloperidol plus promethazine for psychosis induced aggression. Cochrane Database Syst Rev (1): CD005146.
29. Jönsson EG, Edman-Ahlbom B, Sillén A, et al,. 2006. Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. Prog Neuropsychopharmacol Biol Psychiatry 30: 924-933. (Pubitemid 43810174)
30. Jönsson EG, Saetre P, Vares M, StrAlin P, Levander S, Lindström E,. 2011. Use of antipsychotics-an analysis of lifetime treatment in 66 patients with psychoses. Psychiatry Res 187: 80-88.
31. Kane JM,. 2001. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 11 (Suppl 4): S397-S403.
32. Kasckow JW, Zisook S,. 2008. Co-occurring depressive symptoms in the older patient with schizophrenia. Drugs Aging 25: 631-647.
33. Kontis D, Theochari E, Kleisas S, et al,. 2010. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34: 1333-1341.
34. Koponen H, Alaraisanen A, Saari K, et al,. 2008. Schizophrenia and sudden cardiac death: a review. Nord J Psychiatry 62: 342-345.
35. Kornischka J, Cordes J, Agelink MW,. 2007. [ 40 years beta-adrenoceptor blockers in psychiatry ]. Fortschr Neurol Psychiatr 75: 199-210. (Pubitemid 46668350)
36. Lawyer G, Nyman H, Agartz I, et al,. 2006. Morphological correlates to cognitive dysfunction in schizophrenia as studied with Bayesian regression. BMC Psychiatry 6: 31.
37. Leucht S, Kissling W, McGrath J,. 2007a. Lithium for schizophrenia. Cochrane Database Syst Rev (3): CD003834.
38. Leucht S, Kissling W, McGrath J, White P,. 2007b. Carbamazepine for schizophrenia. Cochrane Database Syst Rev (3): CD001258.
39. Levander S, Eberhard J, Lindström E,. 2007. Clinical decision-making during 5 years of antipsychotic treatment. Acta Psychiatr Scand Suppl 116: 17-26. (Pubitemid 47621731)
40. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR,. 2002. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev (1): CD001950.
41. Linde K, Rossnagel K,. 2004. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev (2): CD003225.
42. Lindström E, Farde L, Eberhard J, Haverkamp W,. 2005. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol 8: 615-629. (Pubitemid 41400893)
43. Lipinski JF, Jr., Keck PE Jr., McElroy SL,. 1988. Beta-adrenergic antagonists in psychosis: is improvement due to treatment of neuroleptic-induced akathisia? J Clin Psychopharmacol 8: 409-416. (Pubitemid 19014783)
44. Low NC, Du Fort GG, Cervantes P,. 2003. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. Headache 43: 940-949. (Pubitemid 37238648)
45. Lubman DI, Berk M,. 2010. Pharmacotherapy for co-occurring alcohol and drug disorders in schizophrenia and bipolar disorder: where is the evidence? Acta Neuropsychiatr 22: 95-97.
46. Luo RD, Belleti DA, Tran D, Arcona S, Salen PN,. 2002. National prescribing patterns in the management of extrapyramidal symptoms among patients with schizophrenia. Int J Psychiatry Med 32: 261-269. (Pubitemid 36443436)
47. Mackin P,. 2008. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 23 (Suppl 1): 3-14.
48. Mallinger JB, Lamberti SJ,. 2007. Racial differences in the use of adjunctive psychotropic medications for patients with schizophrenia. J Ment Health Policy Econ 10: 15-22. (Pubitemid 46605737)
49. McIntyre RS, Konarski JZ, Wilkins K, Bouffard B, Soczynska JK, Kennedy SH,. 2006. The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey. Headache 46: 973-982. (Pubitemid 43794749)
50. Merikangas KR, Stevens DE,. 1997. Comorbidity of migraine and psychiatric disorders. Neurol Clin 15: 115-123. (Pubitemid 27098703)
51. Meyer J,. 2007. Drug-drug interactions with antipsychotics. CNS Spectr 12: 6-9.
52. Micallef J, Fakra E, Blin O,. 2006. [ Use of antidepressant drugs in schizophrenic patients with depression ]. Encephale 32: 263-269. (Pubitemid 43670236)
53. Miller DD, McEvoy JP, Davis SM, et al,. 2005. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 80: 33-43. (Pubitemid 41587461)
54. Möller HJ,. 2004. Non-neuroleptic approaches to treating negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 254: 108-116.
55. Morrison JR,. 1975. Catatonia: diagnosis and management. Hosp Community Psychiatry 26: 91-94.
56. Novick D, Bousono M, Suarez D, et al,. 2005. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog Neuropsychopharmacol Biol Psychiatry 29: 972-982. (Pubitemid 41080120)
57. Ortiz A, Cervantes P, Zlotnik G, et al,. 2010. Cross-prevalence of migraine and bipolar disorder. Bipolar Disord 12: 397-403.
58. Pacher P, Kecskemeti V,. 2004. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des 10: 2463-2475. (Pubitemid 38997427)
59. Petrakis IL, Nich C, Ralevski E,. 2006. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull 32: 644-654. (Pubitemid 44412852)
60. Pierre JM,. 2005. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 28: 191-208. (Pubitemid 40364887)
61. Prakash R, Reed RM, Bass AD,. 1984. Combination of phenobarbital and haloperidol in resistant schizophrenia. J Clin Psychopharmacol 4: 362-363.
62. Punay NC, Couch JR,. 2003. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 7: 51-54. (Pubitemid 38915070)
63. Pytliak M, Vargova V, Mechirova V, Felsoci M,. 2011. Serotonin receptors-from molecular biology to clinical applications. Physiol Res 60 (1): 15-25.
64. Rathbone J, Soares-Weiser K,. 2006. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev (4): CD003727.
65. Regier DA, Farmer ME, Rae DS, et al,. 1990. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. J Am Med Assoc 264: 2511-2518.
66. Rosenberg SD, Goodman LA, Osher FC, et al,. 2001. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 91: 31-37. (Pubitemid 32049263)
67. Roth RM, Brunette MF, Green AI,. 2005. Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Curr Psychiatry Rep 7: 283-291. (Pubitemid 41309531)
68. Sakai Y, Dobson C, Diksic M, Aube M, Hamel E,. 2008. Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology 70: 431-439.
69. Schwarz C, Volz A, Li C, Leucht S,. 2008. Valproate for schizophrenia. Cochrane Database Syst Rev (3): CD004028.
70. Shorter E,. 2009. The history of lithium therapy. Bipolar Disord 11 (Suppl 2): 4-9.
71. Silberstein SD, Peres MF, Hopkins MM, et al,. 2002. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 42: 515-518. (Pubitemid 37011824)
72. Silver H,. 2001. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7: 283-304. (Pubitemid 34016086)
73. Silver H,. 2004. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 5: 2053-2058. (Pubitemid 39406107)
74. Silver H, Chertkow Y, Weinreb O, Danovich L, Youdim M,. 2009. Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia? Neurotherapeutics 6: 86-93.
75. Soares KV, McGrath JJ,. 2000. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev (2): CD000204.
76. Stimmel GL,. 1996. Benzodiazepines in schizophrenia. Pharmacotherapy 16: 148S-151S; discussion 166S-168S. (Pubitemid 26397100)
77. Suzuki A, Yasui-Furukori N, Mihara K, et al,. 2003. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit 25: 192-196. (Pubitemid 36373426)
78. Swartz MS, Wagner HR, Swanson JW, et al,. 2006. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 194: 164-172.
79. Vares M, Ekholm A, Sedvall GC, Hall H, Jönsson EG,. 2006. Characterisation of patients with schizophrenia and related psychosis: evaluation of different diagnostic procedures. Psychopathology 39: 286-295. (Pubitemid 44492194)
80. Volz A, Khorsand V, Gillies D, Leucht S,. 2007. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev (1): CD006391.
81. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD,. 1999. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 37: AS81-AS86.
82. World Health Organization. 2007. Collaborating Centre for Drug Statistics Methodology Available at:. Vol. 2007.
83. Zaremba PD, Bialek M, Blaszczyk B, Cioczek P, Czuczwar SJ,. 2006. Non-epilepsy uses of antiepilepsy drugs. Pharmacol Rep 58: 1-12.
84. Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI,. 2000. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 20: 94-98. (Pubitemid 30056360)
85. Zink M, Englisch S, Meyer-Lindenberg A,. 2010. Polypharmacy in schizophrenia. Curr Opin Psychiatry 23: 103-111.